ITEMS IN AFP WITH KEYWORD:
Chronic Obstructive Pulmonary Disease
Glycopyrrolate is a safe option for maintenance treatment to prevent moderate to severe exacerbations in patients with moderate to severe COPD, with only mild and rare adverse effects.
Learn about the latest recommendations from the Global Initiative for Chronic Obstructive Lung Disease, the American College of Physicians, and the National Institute for Health and Care Excellence.
Umeclidinium is an easy-to-use, once-daily, well-tolerated, and relatively low-cost anti-cholinergic agent for maintenance therapy in patients with moderate to severe COPD.
There is very good agreement between arterial and venous measurements of pH and bicarbonate, and fairly good agreement at higher levels between arterial and peripheral measures of oxygen saturation. These authors suggest an algorithm for patients with acute exacerbation of COPD that includes an arte...
Jul 15, 2016 Issue
Screening for Chronic Obstructive Pulmonary Disease: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends against screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults.
Using immediate, in-office spirometry results as the reference standard, seasoned physicians accurately identified COPD severity in approximately one in three patients, underestimating severity in 41% of patients and overestimating severity in 29% of patients. This mismatch seems to be important bec...
Sep 1, 2015 Issue
ACCP/CTS Provide Guidance on Preventing Acute COPD Exacerbations [Practice Guidelines]
The American College of Chest Physicians (ACCP) and Canadian Thoracic Society (CTS) have released a guideline with suggestions and recommendations for preventing COPD exacerbations based on available evidence.
Aclidinium did not decrease all-cause mortality or exacerbations requiring oral steroids, antibiotics, or both. However, aclidinium decreased the number of patients with exacerbations requiring hospitalization and improved quality of life in those with stable COPD.
Indacaterol provides a similar benefit to other long-acting bronchodilators for the treatment of moderate to severe COPD, with once-daily dosing. As with other LABAs, it should be used only as add-on therapy in patients already taking inhaled corticosteroids.
Jun 1, 2014 Issue
Prophylactic Antibiotics for the Prevention of COPD Exacerbation [Cochrane for Clinicians]
Continuous prophylactic antibiotic therapy significantly decreases COPD exacerbations for up to three years. However, it does not decrease mortality, and it puts the patient at risk of antibiotic-resistant colonization and infection.